keyword
MENU ▼
Read by QxMD icon Read
search

5-ARI

keyword
https://www.readbyqxmd.com/read/29730200/bladder-cancer-survival-in-men-using-5-alpha-reductase-inhibitors
#1
Ville J Mäkelä, Andres Kotsar, Teuvo Lj Tammela, Teemu J Murtola
PURPOSE: Androgens may have a role in bladder carcinogenesis. We studied whether use of 5-alpha-reductase inhibitors (5-ARIs) associates with bladder cancer (BCa)-specific mortality in a population-based cohort of men with BCa. MATERIALS AND METHODS: The study cohort consists of 10,720 Finnish men with newly diagnosed BCa during 1997-2012, identified from national cancer registry. Median follow-up was 4.17 years after BCa diagnosis. Hazard ratios (HRs) and 95% confidence intervals (CI) for the risk of BCa death by 5-ARI use were analyzed using Cox regression adjusted for age, gender, co-morbidities, primary bladder cancer treatment and tumor extent at diagnosis...
May 3, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29694707/efficacy-and-safety-of-a-hexanic-extract-of-serenoa-repens-permixon-%C3%A2-for-the-treatment-of-lower-urinary-tract-symptoms-associated-with-benign-prostatic-hyperplasia-luts-bph-systematic-review-and-meta-analysis-of-randomized-controlled-trials-and-observational
#2
Remigio Vela-Navarrete, Antonio Alcaraz, Alfredo Rodríguez-Antolín, Bernardino Miñana López, Jesús M Fernández-Gómez, Javier C Angulo, David Castro Díaz, Javier Romero-Otero, Francisco J Brenes, Joaquín Carballido, José M Molero García, Antonio Fernández-Pro Ledesma, José Manuel Cózar Olmos, José Manasanch Dalmau, Isaac Subirana Cachinero, Michael Herdman, Vincenzo Ficarra
OBJECTIVES: To comprehensively evaluate the efficacy and safety of the hexanic extract of Serenoa repens (HESr, Permixon), at a dose of 320 mg daily, as monotherapy for the treatment of LUTS/BPH. MATERIALS AND METHODS: Systematic review and meta-analysis of randomized and observational studies in patients with LUTS/BPH identified through searches in Medline, Web of Knowledge [ISI], Scopus, the Cochrane Library, and bibliographic references up to March 2017. Articles studying S...
April 25, 2018: BJU International
https://www.readbyqxmd.com/read/29680951/urologists-attitudes-to-sexual-complications-of-luts-bph-treatments
#3
Simone Giona, Indranil Ganguly, Gordon Muir
INTRODUCTION: Many LUTS/BPH treatments currently available may affect sexual function (SD). We wished to assess urologists' attitude and practice in this area. METHODS: Attendees of an international meeting were randomly selected, interviewed and stratified by professional status and LUTS/BPH cases seen per month. There were four questions: treatment options offered, frequency of discussing erectile dysfunction (ED) with each treatment, frequency of discussing ejaculatory dysfunction (EjD) with each treatment, and offering alternative treatment based on the risks of sexual dysfunction...
April 21, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29603785/alpha-1-adrenergic-antagonists-5-alpha-reductase-inhibitors-phosphodiesterase-type-5-inhibitors-and-phytotherapic-compounds-in-men-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-obstruction-a-systematic-review-and-meta-analysis-of-urodynamic
#4
REVIEW
Ferdinando Fusco, Massimiliano Creta, Cosimo De Nunzio, Mauro Gacci, Vincenzo Li Marzi, Enrico Finazzi Agrò
AIMS: To perform a systematic review and meta-analysis of studies evaluating the urodynamic outcomes of alpha-1 adrenergic antagonists (ABs), 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase type 5 inhibitors (PDE5is), and phytotherapic compounds in patients with lower urinary tract symptoms related to benign prostatic obstruction (LUTS/BPO). METHODS: A systematic review of PubMed/Medline, ISI Web of Knowledge, and Scopus databases was performed in June 2017...
March 31, 2018: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/29568063/deregulation-of-atg9a-by-impaired-ar-signaling-induces-autophagy-in-prostate-stromal-fibroblasts-and-promotes-bph-progression
#5
Chen-Yi Jiang, Bo-Yu Yang, Sheng Zhao, Si-Hui Shao, Xiao-Yu Bei, Fei Shi, Qian Sun, Zheng Deng, Xiao-Hai Wang, Bang-Min Han, Fu-Jun Zhao, Shu-Jie Xia, Yuan Ruan
The activation of androgen receptor (AR) signaling plays an essential role in both prostate stromal cells and epithelial cells during the development of benign prostatic hyperplasia (BPH). Here we demonstrated that androgen ablation after 5α-reductase inhibitor (5-ARI) treatment induced autophagy in prostate stromal fibroblasts inhibiting cell apoptosis. In addition, we found that ATG9A expression was increased after androgen ablation, which facilitated autophagic flux development. Knockdown of ATG9A not only inhibited autophagy notably in prostate stromal fibroblasts, but also reduced the volumes of prostate stromal fibroblast and epithelial cell recombinant grafts in nude mice...
March 22, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29548030/risk-of-prostate-cancer-in-men-treated-with-5%C3%AE-reductase-inhibitors-a-large-population-based-prospective-study
#6
Anna Wallerstedt, Peter Strom, Henrik Gronberg, Tobias Nordstrom, Martin Eklund
Background: Studies have shown that 5α-reductase inhibitors (5-ARIs) decrease the risk for low-grade prostate cancer (PC), but results are conflicting concerning high-grade PCs. The objective of the present study is to evaluate the association between 5-ARI treatment for lower urinary tract symptoms and the risk for PC. Methods: This is a population-based prospective study on all men age 40 years and older with at least one prostate-specific antigen (PSA) test in Stockholm County from January 2007 until December 2015...
March 14, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29511582/prognostic-influence-of-5-alpha-reductase-inhibitors-in-patients-with-localized-prostate-cancer-under-active-surveillance
#7
Tayyar Alp Özkan, Oğuz Özden Cebeci, İbrahim Çevik, Özdal Dillioğlugil
Objective: The incidence of prostate adenocarcinoma (PCa) is increased with the use of prostate-specific antigen (PSA). In the current study, we aimed to investigate the impact of 5- alpha- reductase inhibitors (5-ARI) on pathological progression in patients followed by active surveillance (AS). Material and methods: Records of 69 patients with localized prostate cancer under AS (PSA ≤15 ng/mL, PSAD ≤0.20, ≤cT2c, Gleason sum ≤3+3, the number of cancer positive cores ≤3) were evaluated retrospectively...
March 2018: Turkish Journal of Urology
https://www.readbyqxmd.com/read/29379733/the-use-of-5-alpha-reductase-inhibitors-in-the-treatment-of-benign-prostatic-hyperplasia
#8
REVIEW
Eric H Kim, John A Brockman, Gerald L Andriole
Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR) and the need for BPH-related surgery. Both normal and abnormal prostate growth is driven by the androgen dihydrotestosterone (DHT), which is formed from testosterone under the influence of 5-alpha reductase. Thus, 5-alpha reductase inhibitors (5-ARIs) effectively reduce the serum and intraprostatic concentration of DHT, causing an involution of prostate tissue...
January 2018: Asian Journal of Urology
https://www.readbyqxmd.com/read/29187470/the-genomic-alterations-of-5%C3%AE-reductases-and-their-inhibitor-finasteride-s-effect-in-bladder-cancer
#9
Chi-Cheng Chen, Chi-Ping Huang, Yi-Tung Tsai, Teng-Fu Hseih, Chih-Rong Shyr
BACKGROUND/AIM: Since androgens affect urothelial bladder cancer (UBC), we examined whether 5α-reductases (5-AR) have genomic alterations in UBC and whether 5α-reductase inhibitors (5-ARI) affect UBC. MATERIALS AND METHODS: The cBioPortal was used to analyze genomic alternations of 5-ARs in UBC cancer genomic datasets. Next, we used the Taiwan National Health Insurance Research database to conduct a population-based case-control study to investigate the effect of a 5-ARI, finasteride on UBC incidence...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29153901/use-of-5-alpha-reductase-inhibitors-as-alternatives-to-luteinizing-hormone-releasing-hormone-lhrh-analogs-or-anti-androgens-for-prostate-downsizing-before-brachytherapy
#10
Hee Joon Bae, Omar Mian, Dhananjay Vaidya, Theodore L DeWeese, Daniel Y Song
INTRODUCTION: Prostate hypertrophy, median lobe hypertrophy, and pubic arch interference (PAI) are relative contraindications to brachytherapy because of potential morbidity and technical considerations. GnRH analogs or non-steroidal anti-androgens are currently utilized to achieve prostatic downsizing prior to brachytherapy. However, such agents have been associated with effects on body habitus, metabolism, and quality of life. In contrast, 5-alpha reductase inhibitors (5-ARI) are far less frequently associated with these morbidities...
October 10, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29095730/prostate-cancer-prevention-with-5-alpha-reductase-inhibitors-concepts-and-controversies
#11
Michael A Liss, Ian M Thompson
PURPOSE OF REVIEW: We review the concepts surrounding prostate cancer prevention strategies with 5-alpha reductase inhibitors (5-ARIs) and the controversies associated with their use. RECENT FINDINGS: Updated data have shown no increased risk of death from the diagnosis of higher risk cancer; however, 5-ARIs remain controversial and not approved for prostate cancer prevention. SUMMARY: The main theme of the review identifies the success of reducing insignificant prostate cancer and the controversy with the increased association of higher risk prostate cancer by approximately 20%...
January 2018: Current Opinion in Urology
https://www.readbyqxmd.com/read/28856711/rationale-and-design-of-the-canari-study-a-case-control-study-investigating-the-association-between-prostate-cancer-and-5-alpha-reductase-inhibitors-for-symptomatic-benign-prostate-hypertrophy-by-linking-sniiram-and-pathology-laboratories-in-a-specific-region
#12
Lucie-Marie Scailteux, Frédéric Balusson, Sébastien Vincendeau, Nathalie Rioux-Leclercq, Emmanuel Nowak
Benign prostate hypertrophy (BPH) could be associated with low urinary symptoms requiring medical treatment: 5-alpha-reductase inhibitors (5-ARI) or ɑ-blockers. Two clinical trials investigating 5-ARI use in prostate cancer (PCa) primary prevention highlighted a potential safety signal with an increased risk of high-grade PCa. Later observational studies failed to show similar results but have some limits. This paper focuses on describing the protocol of the CANARI study and its feasibility, as regards the matching process of two pseudo-anonymous databases...
February 2018: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/28817869/re-impact-of-combination-therapy-5-alpha-reductase-inhibitors-5-ari-plus-alpha-blockers-ab-on-erectile-dysfunction-and-decrease-of-libido-in-patients-with-luts-bph-a-systematic-review-with-meta-analysis
#13
https://www.readbyqxmd.com/read/28791232/optimising-patient-outcomes-with-photoselective-vaporization-of-the-prostate-pvp-a-review
#14
REVIEW
Claire Pascoe, Darren Ow, Marlon Perera, Henry H Woo, Greg Jack, Nathan Lawrentschuk
Benign prostatic hyperplasia (BPH) is a common pathology causing lower urinary tract symptoms (LUTS) and may significantly impact quality of life. While transurethral resection of the prostate (TURP) remains the gold standard treatment, there are many evolving technologies that are gaining popularity. Photoselective vaporization of the prostate (PVP) is one such therapy which has been shown to be non-inferior to TURP. We aimed to review the literature and discuss factors to optimise patient outcomes in the setting of PVP for BPH...
July 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28789947/impact-of-5%C3%AE-reductase-inhibitors-on-disease-reclassification-among-men-on-active-surveillance-for-localized-prostate-cancer-with-favorable-features
#15
Charles Dai, Vishnu Ganesan, Joseph Zabell, Yaw A Nyame, Nima Almassi, Daniel J Greene, Daniel Hettel, Chad Reichard, Samuel C Haywood, Hans Arora, Anna Zampini, Alice Crane, Jianbo Li, Ahmed Elshafei, Cristina Magi-Galluzzi, Robert J Stein, Khaled Fareed, Michael Gong, J Stephen Jones, Eric A Klein, Andrew J Stephenson
PURPOSE: We determined the effect of 5-ARIs (5α-reductase inhibitors) on disease reclassification in men with prostate cancer optimally selected for active surveillance. MATERIALS AND METHODS: In this retrospective review we identified 635 patients on active surveillance between 2002 and 2015. Patients with favorable cancer features on repeat biopsy, defined as absent Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride or dutasteride within 1 year of diagnosis...
August 5, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28695317/pre-radiotherapy-psa-progression-is-a-negative-prognostic-factor-in-prostate-cancer-patients-using-5%C3%A2-alpha-reductase-inhibitors
#16
Daniel Taussky, Julie Piotte, Kevin C Zorn, Marc Zanaty, Vimal Krishnan, Carole Lambert, Jean-Paul Bahary, Marie-Claude Beauchemin, Maroie Barkati, Cynthia Ménard, Guila Delouya
OBJECTIVE: To investigate the impact of 5‑alpha-reductase inhibitor (5-ARI) use on radiotherapy outcomes for localized prostate cancer. PATIENTS AND METHODS: We included 203 patients on a 5-ARI from our institutional database comprising over 2500 patients who had been treated with either external beam radiotherapy (EBRT) or brachytherapy for localized prostate cancer. Patients received a 5-ARI for urinary symptoms or active surveillance. Cancer progressions at the time of definitive treatment were analyzed according to the following criteria: (a) progression of Gleason score or increase in cancer volume on biopsy, (b) first biopsy positive for cancer after being treated for urinary symptoms with a 5-ARI, and (c) prostate-specific antigen (PSA) progression with or without a previous cancer diagnosis...
January 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28580382/differences-in-the-treatment-of-benign-prostatic-hyperplasia-comparing-the-primary-care-physician-and-the-urologist
#17
Adam J Rensing, Adrienne Kuxhausen, Joel Vetter, Seth A Strope
INTRODUCTION: Benign prostatic hyperplasia is a prevalent chronic condition with expenditures exceeding $1 billion each year. Little is known about management of patients by primary care physicians compared to urologists. We assessed changes in management after medication initiation in these two settings. METHODS: From the Chronic Condition Warehouse 5% sample of Medicare beneficiaries linked to Medicare Part D data, we defined a cohort of men, 66 to 90 years old, with initial prescriptions for alpha-blocker, 5-alpha reductase inhibitor (5-ARI), or both...
May 2017: Urology Practice
https://www.readbyqxmd.com/read/28385453/co-clinical-analysis-of-a-genetically-engineered-mouse-model-and-human-prostate-cancer-reveals-significance-of-nkx3-1-expression-for-response-to-5%C3%AE-reductase-inhibition
#18
Aditya Dutta, Sukanya Panja, Renu K Virk, Jaime Yeji Kim, Roseann Zott, Serge Cremers, David M Golombos, Deli Liu, Juan Miguel Mosquera, Elahe A Mostaghel, Christopher E Barbieri, Antonina Mitrofanova, Cory Abate-Shen
BACKGROUND: Although men on active surveillance for prostate cancer (PCa) may benefit from intervention with 5α-reductase inhibitors (5-ARIs), it has not been resolved whether 5-ARIs are effective for delaying disease progression and, if so, whether specific patients are more likely to benefit. OBJECTIVE: To identify molecular features predictive of patient response to 5-ARIs. DESIGN, SETTING, AND PARTICIPANTS: Nkx3.1 mutant mice, a model of early-stage PCa, were treated with the 5-ARI finasteride, and histopathological and molecular analyses were performed...
October 2017: European Urology
https://www.readbyqxmd.com/read/28216328/outcomes-of-prostate-cancer-screening-by-5%C3%AE-reductase-inhibitor-use
#19
Teemu J Murtola, Anniina Virkku, Kirsi Talala, Ulf-Håkan Stenman, Kimmo Taari, Teuvo L J Tammela, Anssi Auvinen
PURPOSE: Prostate cancer screening with prostate specific antigen reduces prostate cancer mortality but leads to over diagnosis of indolent prostate cancer. The use of 5α-reductase inhibitors lowers prostate specific antigen and in theory could affect the performance of prostate specific antigen based screening. We evaluated the outcomes of prostate cancer screening in 5α-reductase inhibitors users. MATERIALS AND METHODS: The study was performed in FinRSPC (Finnish Randomized Study of Screening for Prostate Cancer)...
August 2017: Journal of Urology
https://www.readbyqxmd.com/read/28164396/improved-multiparametric-mri-discrimination-between-low-risk-prostate-cancer-and-benign-tissues-in-a-small-cohort-of-5%C3%AE-reductase-inhibitor-treated-individuals-as-compared-with-an-untreated-cohort
#20
Olga Starobinets, John Kurhanewicz, Susan M Noworolski
The purpose of this study was to determine whether 5α-reductase inhibitors (5-ARIs) affect the discrimination between low-grade prostate cancer and benign tissues on multiparametric MRI (mpMRI). Twenty men with biopsy-proven Gleason 3 + 3 prostate cancer and 3 T mpMRI were studied. Ten patients (Tx) had been receiving 5-ARIs for at least a year at scan time. Ten untreated patients (Un) were matched to the treated cohort. For each subject two regions of interest representing cancerous and benign tissues were drawn within the peripheral zone of each prostate, MR measures evaluated, and cancer contrast versus benign (contrast = (MRTumor  - MRHealthy )/MRHealthy ) calculated...
May 2017: NMR in Biomedicine
keyword
keyword
68180
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"